• 1
    Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl. Cancer Inst. 1998; 90: 766771.
  • 2
    Freedland SJ. Screening, risk assessment, and the approach to therapy in patients with prostate cancer. Cancer 2011; 117: 11231135.
  • 3
    Cooperberg MR, Pasta DJ, Elkin EP et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J. Urol. 2005; 173: 19381942.
  • 4
    D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969974.
  • 5
    Dorin RP, Daneshmand S, Lassoff MA et al. Long-term outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostate-specific antigen era. Urology 2012; 79: 626631.
  • 6
    Edge SB , Byrd DR , Compton CC , Fritz AG , Greene FL , Trotti A (eds). American Joint Committee on Cancer Staging Manual, 7th edn. Springer, New York, 2009.
  • 7
    Sobin L , Gospodarowicz M , Wittekind C (eds). TNM Classification of Malignant Tumors, 7th edn. John Wiley & Sons, Inc, Hoboken, NJ, 2009.
  • 8
    Kamidono S, Ohshima S, Hirao Y et al. Evidence-based clinical practice Guidelines for Prostate Cancer (Summary – JUA 2006 Edition). Int. J. Urol. 2008; 15: 118.
  • 9
    Mohler J, Bahnson RR, Boston B et al. NCCN clinical practice guidelines in oncology: prostate cancer. J. Natl. Compr. Canc. Netw. 2010; 8: 13431351.
  • 10
    Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur. Urol. 2008; 53: 6880.
  • 11
    Kawakami J, Cowan JE, Elkin EP et al. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006; 106: 17081714.
  • 12
    Graff JN, Mori M, Li H et al. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. J. Urol. 2007; 177: 13071312.
  • 13
    Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J. Natl. Cancer Inst. 2003; 95: 981989.
  • 14
    Fujimoto H, Nakanishi H, Miki T et al. Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA. Int. J. Urol. 2011; 18: 876881.
  • 15
    Abrahamsson P-A. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur. Urol. 2010; 57: 4959.
  • 16
    Matsuda T, Matsuda A. Time trends in prostate cancer mortality between 1950 and 2008 in Japan, the USA and Europe based on the WHO mortality database. Jpn. J. Clin. Oncol. 2011; 41: 1389.
  • 17
    Akaza H, Usami M, Hinotsu S et al. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn. J. Clin. Oncol. 2004; 34: 329336.
  • 18
    Hinotsu S, Akaza H, Usami M et al. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn. J. Clin. Oncol. 2007; 37: 775781.
  • 19
    Cooperberg MR, Hinotsu S, Namiki M et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J. Clin. Oncol. 2009; 27: 43064313.
  • 20
    Boorjian SA, Karnes RJ, Viterbo R et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 2011; 117: 28832891.
  • 21
    Boorjian SA, Blute ML. Surgical management of high risk prostate cancer: the Mayo Clinic experience. Urol. Oncol. 2008; 26: 530532.
  • 22
    Bolla M, Van Tienhoven G, Warde P et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010; 11: 10661073.
  • 23
    Horwitz EM, Bae K, Hanks GE et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J. Clin. Oncol. 2008; 26: 24972504.
  • 24
    D'Amico AV, Whittington R, Malkowicz SB et al. Recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J. Clin. Oncol. 1999; 17: 168172.
  • 25
    Widmark A, Klepp O, Solberg A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Lancet 2009; 373: 301308.
  • 26
    Messing EM, Manola J, Yao J et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006; 7: 472479.
  • 27
    Sella A, Zisman A, Kovel S et al. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Urology 2008; 71: 323327.
  • 28
    Mellado B, Font A, Alcaraz A et al. Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br. J. Cancer 2009; 101: 12481252.
  • 29
    Chi KN, Chin JL, Winquist E et al. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J. Urol. 2008; 180: 565570.
  • 30
    Agarwal N, Sonpavde G, Sternberg CN. Novel molecular targets for the therapy of castration-resistant prostate cancer. Eur. Urol. 2012; 61: 950960.